Medicare Enrolled

Dr. Mina Baratifar, PA-S

Speech-Language Pathologist · Dallas, TX
Low-engagement
8390 LYNDON B JOHNSON FWY STE 1000, Dallas, TX 75243
2147509977
In practice since 2014 (11 years)
NPI: 1922402189 verify on NPPES ↗
High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Baratifar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Baratifar? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Baratifar

Dr. Mina Baratifar is a speech-language pathologist specialist in Dallas, TX, with 11 years of NPI registration.

Between the years covered by Open Payments, Dr. Baratifar received a total of $6,718 from 52 pharmaceutical and/or device companies across 317 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in speech-language pathologist. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Baratifar is High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 11 years in practice $6,718 industry payments

Industry Payment Transparency

Open Payments through 2024 ↗
$6,718
Total received (2021-2024)
Avg $1,679/year across 4 years
Top 33% in TX for speech-language pathologist
52
Companies
317
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,718 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,044
2023
$2,667
2022
$1,569
2021
$438

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$1,302
ARGENX US, INC.
$508
UCB, Inc.
$357
Novartis Pharmaceuticals Corporation
$312
Teva Pharmaceuticals USA, Inc.
$278
Lilly USA, LLC
$267
Merz Pharmaceuticals, LLC
$223
Genentech USA, Inc.
$209
ACADIA Pharmaceuticals Inc
$207
Sumitomo Pharma America, Inc.
$175
Averitas Pharma Inc.
$171
PFIZER INC.
$160
Biogen, Inc.
$155
Celgene Corporation
$149
Otsuka America Pharmaceutical, Inc.
$140
Alexion Pharmaceuticals, Inc.
$136
Biohaven Pharmaceutical Holding Company Ltd.
$131
Neurelis, Inc.
$129
AbbVie Inc.
$121
CSL Behring
$112
Lundbeck LLC
$109
JAZZ PHARMACEUTICALS INC.
$109
Eisai Inc.
$97
Ipsen Biopharmaceuticals, Inc
$97
Neurocrine Biosciences, Inc.
$95
Octapharma USA, Inc.
$91
SK Life Science, Inc.
$74
Avanir Pharmaceuticals, Inc.
$62
Amneal Pharmaceuticals LLC
$61
EISAI INC.
$53
Kyowa Kirin, Inc.
$51
SCILEX PHARMACEUTICALS INC.
$50
Alnylam Pharmaceuticals Inc.
$44
CATALYST PHARMACEUTICALS, INC.
$43
TG Therapeutics, Inc.
$41
Biohaven Pharmaceuticals, Inc.
$40
UPSHER-SMITH LABORATORIES LLC
$34
Marinus Pharmaceuticals, Inc.
$33
MITSUBISHI TANABE PHARMA AMERICA, INC.
$31
Horizon Therapeutics plc
$30
GENZYME CORPORATION
$29
Sunovion Pharmaceuticals Inc.
$28
IMPEL PHARMACEUTICALS INC.
$21
Life Molecular Imaging Ltd
$20
Corium, LLC
$20
Takeda Pharmaceuticals U.S.A., Inc.
$19
Avion Pharmaceuticals
$18
TG THERAPEUTICS, INC.
$17
ANI Pharmaceuticals, Inc.
$16
Acorda Therapeutics, Inc
$14
NS Pharma, Inc.
$13
Xeris Pharmaceuticals, Inc.
$12
Top 3 companies account for 32.3% of total payments
Associated products mentioned in payments ›
ADUHELM · AJOVY · AMYVID · APTIOM · AUSTEDO · Adlarity · Austedo XR · BOTOX · BRIUMVI · Briviact · COMIRNATY · DAYBUE · DUOPA · DYSPORT · Dhivy · Dysport · EMGALITY · EPIDIOLEX · Enspryng · FYCOMPA · Fintepla · Fycompa · GAMMAGARD · GVOKE PFS · Hizentra · INBRIJA · INGREZZA · KESIMPTA · Leqembi · NEURACEQ · NOURIANZ · NUEDEXTA · NUPLAZID · NURTEC ODT · Nuedexta · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONPATTRO · PANZYGA · PURIFIED CORTROPHIN GEL · QULIPTA · QUTENZA · RADICAVA · REXULTI · RYTARY · Rystiggo · SKYCLARYS · SOLIRIS · Skyclarys · TOSYMRA · TYSABRI · Trudhesa · UBRELVY · ULTOMIRIS · UPLIZNA · VALTOCO · VILTEPSO · VYALEV · VYEPTI · VYVGART · VYVGART HYTRULO · Xeomin · ZEMBRACE SYMTOUCH · ZEPOSIA · ZTALMY · ZTLido
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a speech-language pathologist specialist in Dallas?
Compare speech-language pathologists in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse speech-language pathologists nearby

Geographic Context

Speech-language pathologists within 10 mi
3,453
Per 100K population
132.6
County median income
$74,149
Nearest hospital
NEXUS CHILDRENS HOSPITAL DALLAS
0.0 mi

Data Sources

Provider Registry ✓ NPPES Weekly updates
Medicare Enrollment ✓ PECOS Monthly updates
Practice Data — No data N/A
Industry Payments ✓ Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Baratifar is a speech-language pathologist specialist, with low-engagement industry engagement.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Does Dr. Baratifar receive payments from pharmaceutical companies?
Yes. Dr. Baratifar received a total of $6,718 from 52 companies across 317 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently High for Dr. Baratifar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Same specialty & city
Speech-Language Pathologists in Dallas
Browse speech-language pathologists in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Speech-Language Pathologists in TX
Speech-language pathologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Speech-Language Pathologists in TX
Which TX speech-language pathologists receive the most from drug and device companies.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
By company
ARGENX US, INC. Payments to Doctors
See all physicians who received payments from ARGENX US, INC.
By company
UCB, Inc. Payments to Doctors
See all physicians who received payments from UCB, Inc.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →